openPR Logo
Press release

Angiosarcoma gets orphan drug as Propranolol by EC

07-04-2017 10:30 AM CET | Health & Medicine

Press release from: KuicK Research

European Commission has granted Orphan Drug Designation to Propranolol for the treatment of Angiosarcoma, a lethal form of soft tissue sarcoma. Propranolol has been commonly used in the treatment of high blood pressure.

The EMA’s designation of orphan status is granted to encourage new developments and therapies for rare diseases and disorders. Orphan status can be granted to those diseases that are rare. These incentives include protocol assistance, i.e. scientific advice specific for designated orphan medicines, and 10 years of market exclusivity once the medicine is on the market.

“Global Orphan Drug Clinical Pipeline Insight 2022” reports by kuick research gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan designated drugs commercially available in the global market and around 800 drugs in clinical development phase.

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

1. Introduction to Orphan Drug

2. Favorable Market Dynamics for Orphan Drugs Commercialization
2.1 Economic Viability
2.2 Drug Patent Expiry
2.3 Financial & Non-Financial Incentives
2.4 Patent & Market Exclusivity
2.5 R&D Investment

3. Global Orphan Drug Market Overview

4. Global Orphan Drug Market Segment Analysis
4.1 Biological & Non-Biological Orphan Drugs
4.2 Therapeutic Segmentation
4.3 Regional Segmentation

5. Global Orphan Drug Clinical Pipeline Overview

6. US Orphan Drug Market Overview
6.1 Orphan Drug Designation Criteria
6.2 Market Overview
6.3 Reimbursement Policy

7. Europe Orphan Drug Market Overview
7.1 Orphan Drug Designation Criteria
7.2 Market Overview
7.3 Reimbursement Policy

8. Asia Orphan Drug Market Overview
8.1 Orphan Drug Designation Criteria
8.2 Market Overview
8.3 Reimbursement Policy


9. FDA Regulation for Clinical Trials Orphan Designated Drugs
9.1 Content & Format of a Request for Written Recommendations
9.2 Provision for Granting & Refusing Written Recommendations
9.3 Content and Format of a Request for Orphan Drug Designation
9.4 Verification of Orphan Drug Status & Resident Agent for Foreign Sponsor
9.5 Timing of Requests for Orphan Drug Designation & Designation of Already Approved Drugs
9.6 Deficiency Letters and Granting Orphan Drug Designation
9.7 Refusal to Grant Orphan Drug Designation
9.8 Amendment & Change in Ownership to Orphan Drug Designation
9.9 Publication & Revocation of Orphan Drug Designations
9.10 Annual Reports of Holder of Orphan Drug Designation
9.11 Scope & FDA Recognition of Orphan Drug Exclusive Approval
9.12 Protocols for Investigations & Availability of Information

10. EMA Regulations for Clinical Trials of Orphan Designated Drugs
10.1 Committee for Orphan Medicinal Products
10.2 How to Apply for Orphan Designation in Europe
10.3 Marketing Authorization & Market Exclusivity
10.4 Transferring an Orphan Designation to another Sponsor
10.5 Mandatory Submission of Annual Report On Development
10.6 Incentives for Micro, Small and Medium-Sized Enterprises
10.7 Fee Reductions for Designated Orphan Medicinal Products
10.8 Procedure for Orphan Designation & Incentives for R&D (Regulation (EC) No 141/2000)

11. Asian Regulations for Clinical Trials of Orphan Designated Drugs
11.1 Taiwan Rare Disease and Orphan Drug Act
11.2 Japan Orphan Drug Regulation

12. Global Orphan Drugs Clinical Pipeline Insight & Patent Analysis by Company, Country, Indication & Phase
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration
12.11 Registered

13. Marketed Orphan Drugs Clinical Insight & Patent Analysis by Company, Country & Indication

14. Discontinued & Suspended Orphan Drugs in Clinical Trials
14.1 No Development Reported
14.2 Discontinued
14.3 Preregistration-Submission Withdrawal
14.4 Market Withdrawal
14.5 Suspended

15. Competitive Landscape
15.1 AOP Orphan
15.2 Agenus
15.3 Alexion
15.4 Bristol Myers Squibb
15.5 Biogen Idec
15.6 Celgene
15.7 Eli Lilly
15.8 Genethon
15.9 Genzyme Corporation
15.10 Glaxosmithkline
15.11 Merck
15.12 Novartis Pharmaceuticals
15.13 Orphan Europe
15.14 Pfizer
15.15 Prosensa
15.16 Rare Disease Therapeutics
15.17 Roche
15.18 Sanofi
15.19 Shire
15.20 Teva Pharmaceutical

Download Report: https://www.kuickresearch.com/page-Pharmaceutical%20and%20Healthcare.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Angiosarcoma gets orphan drug as Propranolol by EC here

News-ID: 607423 • Views: 180

More Releases from KuicK Research

Stem Cell Therapy Revolutionizing Conventional Therapy Market
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
Cell Therapy to Transform Immuno Oncology Landscape
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025
"US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025" Report Highlights: US Breast Cancer Drug Market Opportunity: US$ 20 Billion US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class and Patient Segment US Breast Cancer Marketed Drugs: 42 Drugs US Breast Cancer Drug Clinical Pipeline: 317 Drugs Dosage and Pricing Insight for Preventive and Treatment Drugs US Breast Cancer Drug Market Dynamics For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report:
Download Global Cell Therapy Market, Clinical Trials, Therapy Price and Opportun …
"Global Cell Therapy Market, Clinical Trials, Therapy Price and Opportunity Insight 2026" Report Highlights: Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 Cell Therapy Clinical Trial Insight by Indication, Company and Country Global Cell Therapy Clinical Pipeline: 767 Cell Therapies Globally Marketed Cell Therapies: 25 Cell Therapies Maximum Number of Marketed Cell Therapies In USA: 15 Therapies Price and Product Insight By Region/Country Regional Analysis of the Cell Therapy Market

All 5 Releases


More Releases for Orphan

Global Orphan Drug Pipeline & Regulatory Insight 2025
” Global Orphan Drug Pipeline & Regulatory Insight 2025” Report Highlights: Global Orphan Drug Market Overview: US$ 260 Billion Opportunity Global Orphan Drug market by Segment Regulatory Landscape: USA, Europe & Asia Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia Global Orphan Drug Clinical Pipeline Insight: 973 Drugs Marketed Orphan Drug Clinical Insight: 366 Drugs Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Orphan-Drug-Pipeline-%26-Regulatory-Insight-2025 Report TOC Orphan Drugs: Regimens For Rare Diseases Drivers of Orphan Drug Commercialization 2.1 Cost
Global Orphan Drug Pipeline & Regulatory Insight 2025
” Global Orphan Drug Pipeline & Regulatory Insight 2025″ Report Highlights: Global Orphan Drug Market Overview: US$ 260 Billion Opportunity Global Orphan Drug market by Segment Regulatory Landscape: USA, Europe & Asia Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia Global Orphan Drug Clinical Pipeline Insight: 973 Drugs Marketed Orphan Drug Clinical Insight: 366 Drugs Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Orphan-Drug-Pipeline-%26-Regulatory-Insight-2025 Orphan Drugs: Regimens For Rare Diseases Drivers of Orphan Drug Commercialization 2.1 Cost
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the
Global Orphan Drug Clinical Pipeline Insight 2022
“Global Orphan Drug Clinical Pipeline Insight 2022” report gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan